Publications by authors named "Collette A Goode"
Article Synopsis
- The study emphasizes the urgent need for effective diagnostic methods for identifying candidates for disease-modifying therapies, using a mix of plasma biomarkers and digital cognitive assessments.
- Researchers tested a tablet-based cognitive assessment and plasma biomarkers on 309 older adults to predict amyloid positivity, disease severity, and functional decline.
- Results show that combining certain plasma markers with cognitive assessments offers a highly accurate way to predict dementia-related conditions, indicating potential for scalable diagnostic approaches in clinical settings.
Objectives: Dementia poses one of the greatest global health challenges, affecting 50 million people worldwide. With 10 million new cases each year, dementia is a growing burden, particularly in low- and middle-income countries (LMIC). This study aimed to identify the facilitators and barriers to providing quality dementia assessment and care in LMICs from a global health perspective.
View Article and Find Full Text PDFBackground: Timely diagnosis of dementia is a global healthcare priority, particularly in low to middle income countries where rapid increases in older adult populations are expected.
Objective: To investigate global perspectives on the role of brief cognitive assessments (BCAs) in dementia diagnosis, strengths and limitations of existing measures, and future directions and needs.
Methods: This is a qualitative study of 18 dementia experts from different areas of the world.
Background: β-amyloid (Aβ) and tau positron emission tomography (PET) detect the pathological changes that define Alzheimer's disease (AD) in living people. Cognitive measures sensitive to Aβ and tau burden may help streamline identification of cases for confirmatory AD biomarker testing.
Methods: We examined the association of Brain Health Assessment (BHA) tablet-based cognitive measures with dichotomized Aβ -PET status using logistic regression models in individuals with mild cognitive impairment (MCI) or dementia (N = 140; 43 Aβ-, 97 Aβ+).
Article Synopsis
- The Brain Health Assessment-Cognitive Score (BHA-CS) was developed to assess cognitive health and monitor disease progression in older adults, both cognitively normal and those with cognitive impairments.
- Through a study involving over 800 participants, the BHA-CS demonstrated strong reliability and identified cognitive decline effectively, detecting significant changes in 75% of dementia patients and 44% of those with mild cognitive impairment.
- The assessment also revealed that cognitively normal individuals with higher amyloid beta levels performed worse on the BHA-CS over time, indicating its utility in early detection of neurodegenerative diseases.